Sana Biotechnology

Sana Biotechnology, Inc. is a clinical-stage biotechnology company based in Seattle, Washington, with additional locations in Cambridge, Massachusetts, and San Francisco, California. Founded in 2018, Sana focuses on developing engineered cells as medicines to treat diseases by repairing or replacing cells in the body. The company utilizes advanced platforms for both *ex vivo* and *in vivo* cell engineering. Sana originated from Flagship Pioneering's labs and has made significant strides since its inception. Key milestones include the acquisition of Ocata Therapeutics, a successful IPO in 2021, and collaborations with Vertex Pharmaceuticals to develop therapies for type 1 diabetes. The company employs over 200 people and aims to transform medicine through integrated technologies in stem cell biology, immunology, and manufacturing. Sana's mission is to enable treatments for untreatable diseases by repairing and replacing cells, while also focusing on scalable and cost-efficient manufacturing processes to enhance therapy accessibility.